Addition of vitamin B12 to exercise training improves cycle ergometer endurance in advanced COPD patients: A randomized and controlled study

What Was Tested

Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.

Vitamin B12 is essential in the homocysteine, mitochondrial, muscle and hematopoietic metabolisms, and its effects on exercise tolerance and kinetics adjustments of oxygen consumption (V'O2p) in rest-to-exercise transition in COPD patients are unknown.

This randomized, double-blind, controlled study aimed to verify a possible interaction between vitamin B12 supplementation and these outcomes.

Who Took Part

According to the abstract, 69 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Cyanocobalamin (Vitamin B12) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Cyanocobalamin (Vitamin B12), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Cyanocobalamin (Vitamin B12) could be set against what happens without it.

The timeline in the abstract includes 8 weeks.

What Was Measured

This randomized, double-blind, controlled study aimed to verify a possible interaction between vitamin B12 supplementation and these outcomes.

The subject headings attached to it are Dietary Supplements, Exercise, Exercise Test, Exercise Therapy, Exercise Tolerance, Oxygen Consumption and Physical Endurance.

The authors tagged it with the keywords Chronic obstructive lung disease, Nutrition, Oxygen uptake kinetics and Vitamin B12.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12) in 69 patients over 8 weeks.

The publication is from 2017 (Respiratory medicine), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.